Novartis Bounces Back From COVID-19 And Cosentyx Keeps Climbing
Business Nearly Back To Normal
Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.
